New ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ will improve patient lives by advancing groundbreaking diagnostic and prognostic technologies.
The FDA now recommends the same assessment questions for all donors, regardless of gender or sexual orientation. ARUP Blood Services is one of the first donor centers to update processes in response.
ARUP Laboratories has received FDA approval for its companion diagnostic immunoassay, AAV5 DetectCDx™, which helps determine patient eligibility for a new gene therapy for severe hemophilia A.
ARUP and Gestalt Diagnostics announced a partnership under which ARUP will adopt Gestalt’s PathFlow® platform as a foundation for future digital pathology initiatives.
Efforts to train more medical laboratory scientists have been greatly boosted by $3 million in federal funds for a clinical lab training center that ARUP will build with the University of Utah.
The U.S. Food and Drug Administration (FDA) has updated its guidelines to allow individuals who lived or worked in the United Kingdom, France, or Ireland to donate blood and platelets.
ARUP’s culture of caring has earned it Utah Business magazine’s Best Companies To Work For Award for a fifth consecutive year.
ARUP’s International Organization for Standardization (ISO) 15189 accreditation assessment has successfully concluded, and results confirm the consistently high quality of ARUP’s operations.
The European Commission’s approval of BioMarin’s novel gene therapy for severe hemophilia A has paved the way for ARUP’s AAV5 DetectCDx™ Kit to become the first ARUP-developed test used in Europe.
NanoSpot.ai’s European commercialization agreement is the first for an antibody test originally developed through an ARUP/University of Utah/Techcyte partnership.